Alterations of pRb1-cyclin D1-cdk4/6-p16INK4A pathway in endometrial carcinogenesis

Cancer Letters

Volumn 203, Issue 1, 2004, Pages 1-12

  Semczuk, Andrzej ^a   Jakowicki, Jerzy Andrzej ^a  

^a Lublin University   (Poland)

Author keywords

CDK4; CDK6; Cyclin D1; Endometrial cancer; P16INK4A; RB1

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; PROTEIN P16; RETINOBLASTOMA PROTEIN;

ALLELIC IMBALANCE; CANCER CELL CULTURE; CANCER INVASION; CARCINOGENESIS; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL HETEROGENEITY; CELL PROLIFERATION; CELL TRANSFORMATION; DEREGULATION; ENDOMETRIUM CARCINOMA; GENE LOCUS; GENE MAPPING; HUMAN; METASTASIS; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR CELL LINE; UTERUS CANCER;

EID: 0345167184     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2003.09.012     Document Type: Article

References (106)

1. Michalides R. Prognosis for G1 cell-cycle regulators: useful for predicting course of disease and for assessment of therapy in cancer. J. Pathol. 188:1999;341-343.
2. Sherr C.J. The Pezcoller Lecture: Cancer cell cycles revisited. Cancer Res. 60:2000;3689-3695.
3. Milde-Langosch K., Riethdorf S. Role of cell-cycle regulatory proteins in gynecological cancer. J. Cell Physiol. 196:2003;224-244.
4. Bartek J., Bartkova J., Lukas J. The retinoblastoma protein pathway in cell cycle control and cancer. Exp. Cell Res. 237:1997;1-6.
5. Collins K., Jacks T., Pavletich N.P. The cell cycle and cancer. Proc. Natl. Acad. Sci. USA. 94:1997;2776-2778.
6. Voojis M., Berns A. Developmental defects and tumor predisposition in Rb mutant mice. Oncogene. 18:1999;5293-5303.
7. Friend S.H., Bernards S., Rogelj S., Weinberg R.A., Rapaport J.M., Albert D.M., Dryja T.P. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature. 323:1986;643-646.
8. Lee W.-H., Bookstein R., Hong F., Young L.-J., Shew J.Y., Lee E.Y.-H.P. Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science. 235:1987;1394-1399.
9. Knudson A.G. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. USA. 68:1971;820-823.
10. Knudson A.G. Antioncogenes and human cancer. Proc. Natl. Acad. Sci. USA. 90:1993;10914-10921.
11. Weinberg R.A. Tumor suppressor genes. Science. 254:1991;1138-1146.
12. Weinberg R.A. The retinoblastoma protein and cell-cycle control. Cell. 81:1995;323-330.
13. Hesketh R. The oncogene and tumour suppressor gene. 2nd ed :1997;FactsBook Academic Press, San Diego London.
14. Muller H., Lukas J., Schneider A., Warthoe P., Bartek J., Eilers M., Strauss M. Cyclin D1 expression is regulated by the retinoblastoma protein. Proc. Natl. Acad. Sci. USA. 91:1994;2945-2949.
15. Sherr C.J., Roberts J.M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9:1995;1149-1163.
16. Serrano M., Hannon G.J., Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 366:1993;704-707.
17. INK4A. Exp. Cell Res. 237:1997;7-13.
18. Michalides R.J.A.M. Cell cycle regulators: mechanisms and their role in aetiology, prognosis, and treatment of cancer. J. Clin. Pathol. 52:1999;555-568.
19. Jeyarajah A., Oram D., Jacobs I. Molecular events in endometrial carcinogenesis. Int. J. Gynecol. Cancer. 6:1996;425-438.
20. Lax S.F., Kurman R.J. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses. Verh. Dtsch. Ges. Path. 81:1997;228-232.
21. Kim J.W., Kim S.H., Kim Z.T., Kim D.K. Clinicopathologic and biological parameters predicting the prognosis in endometrial cancer. Yonsei Med. J. 43:2002;769-778.
22. Miturski R., Bogusiewicz M., Ciotta C., Bignami M., Gogacz M., Bournouf D. Mismatch repair genes and microsatellite instability as molecular markers for gynecological cancer detection. Exp. Biol. Med. 227:2002;579-586.
23. Salvesen H.B., Akslen L.A. Molecular pathogenesis and prognostic factors in endometrial carcinoma. APMIS. 110:2002;673-689.
24. Sasano H., Comerford J., Silverberg S.G., Garrett C.T. An analysis of abnormalities of the retinoblastoma gene in human ovarian and endometrial carcinoma. Cancer. 66:1990;2150-2154.
25. Enomoto T., Fujita M., Inoue M., Nakazawa-Miyamoto A., Tanizawa O., Nomura T. Alterations of the Rb gene and its association with Ki-ras activation and p53 inactivation in endometrial carcinoma. Mol. Carcinog. 8:1993;132-137.
26. Yaginuma Y., Katayama H., Kawai K., Duenas J.C., Ishikawa M. Analysis of the retinoblastoma gene in human endometrial carcinoma. Obstet. Gynecol. 87:1996;755-759.
27. Tritz D., Pieretti M., Turner S., Powell D. Loss of heterozygosity in usual and special variant carcinomas of the endometrium. Hum. Pathol. 28:1997;607-612.
28. Sirchia S.M., Sironi E., Grati F.R., Serafini P., Garagiola I., Rosella F., et al. Losses of heterozygosity in endometrial adenocarcinomas: Positive correlations with histopathological parameters. Cancer Genet. Cytogenet. 121:2000;156-162.
29. Semczuk A., Marzec B., Roessner A., Jakowicki J.A., Wojcierowski J., Schneider-Stock R. Loss of heterozygosity of the retinoblastoma gene is correlated with the altered pRb expression in endometrial cancer. Virchows Arch. 441:2002;577-583.
30. Shimizu T., Toguchida J., Kato M.V., Kaneko A., Ishizaki K., Sasaki M.S. Detection of mutations of the RB1 gene in retinoblastoma patients by using exon-by-exon PCR-SSCP analysis. Am. J. Hum. Genet. 54:1994;793-800.
31. Wadayama B., Toguchida J., Shimizu T., Ishizaki K., Sasaki M.S., Kotoura Y., Yamamuro T. Mutation spectrum of the retinoblastoma gene in osteosarcomas. Cancer Res. 54:1994;3042-3048.
32. Sellers W.R., Kaelin W.G. Jr. Role of the retinoblastoma protein in the pathogenesis of human cancer. J. Clin. Oncol. 15:1997;3301-3312.
33. Stirzaker C., Millar S., Paul C.L., Warnecke P.M., Harrison J., Vincent P.C., et al. Extensive DNA methylation spanning the Rb promoter in retinoblastoma tumors. Cancer Res. 57:1997;2229-2237.
34. Greger V., Debus N., Lohmann D., Hopping W., Passarge E., Horsthemke B. Frequency and parental origin of hypermethylated RB1 alleles in retinoblastoma. Hum. Genet. 94:1994;491-496.
35. Gonzalez-Gomez P., Bello M.J., Alonso M.E., Arjona D., Lomas J., de Campos J.M., et al. CpG island methylation status and mutation analysis of the RB1 gene essential promoter region and protein-binding pocket domain in nervous system tumours. Br. J. Cancer. 88:2003;109-114.
36. Semczuk A., Schneider-Stock R., Berbec H., Marzec B., Jakowicki J.A., Roessner A. K-ras exon 2 point mutations in human endometrial cancer. Cancer Lett. 164:2001;207-212.
37. Geradts J., Kratzke R.A., Crush-Stanton S., Wen S.F., Lincoln C.E. Wild-type and mutant retinoblastoma protein in paraffin sections. Mod. Pathol. 9:1996;339-347.
38. Niemann T.H., Yilmaz A.G., McGaughy V.R., Vaccarello L. Retinoblastoma protein expression in endometrial hyperplasia and carcinoma. Gynecol. Oncol. 65:1997;232-236.
39. Ambros R.A., Vigna P.A., Figge J., Kallakury B.V.S., Mastrangelo A., Eastman A.Y., et al. Observations on tumor and metastatic suppressor gene status in endometrial carcinoma with particular emphasis on p53. Cancer. 73:1994;1686-1692.
40. Li S.-F., Shiozawa T., Nakayama K., Nikaido T., Fujii S. Stepwise abnormality of sex steroid hormone receptors, tumor suppressor gene products (p53 and Rb), and cyclin E in uterine endometrioid carcinoma. Cancer. 77:1996;321-329.
41. Milde-Langosch K., Riethdorf L., Bamberger A.-M., Loning T. P16/MTS1 and pRB expression in endometrial carcinomas. Virchows Arch. 434:1999;23-28.
42. Skomedal H., Kristensen G.B., Nesland J.M., Borresen-Dale A.-L., Trope C., Holm R. TP53 alterations in relation to the cell cycle-associated proteins p21, cyclin D1, CDK4, RB, MDM2, and EGFR in cancers of the uterine corpus. J. Pathol. 187:1999;556-562.
43. Semczuk A., Schneider-Stock R., Miturski R., Skomra D., Tomaszewski J., Roessner A., Jakowicki J.A. RB protein expression in human endometrial carcinomas - an immunohistochemical study. Pathol. Res. Pract. 196:2000;41-46.
44. Ioachim E.E., Goussia A.C., Kitsiou E.G., Charalabopoulos K., Mermiga K., Stefanaki S. Immunohistochemical expression of retinoblastoma gene product in normal, hyperplastic and malignant endometrium. Correlation with p53 protein expression, c-erbB-2, hormone receptors' status and proliferative activity. Dis. Markers. 18:2002;143-152.
45. INK4A and cdk4) in human endometrial cancer: correlation with clinicopathological features. Arch. Gynecol. Obstet. 2003;. in press.
46. Milde-Langosch K., Bamberger A.-M., Goemann C., Rossing E., Rieck G., Kelp B., Loning T. Expression of cell-cycle regulatory proteins in endometrial carcinomas: correlations with hormone receptor status and clinicopathologic parameters. J. Cancer Res. Clin. Oncol. 127:2001;537-544.
47. Semczuk A., Skomra D., Cybulski M., Jakowicki J.A. Immunohistochemical analysis of MIB-1 proliferative activity in human endometrial cancer. Correlation with clinicopathological parameters, patient outcome, retinoblastoma immunoreactivity and K-ras codon 12 point mutations. Histochem. J. 33:2001;193-200.
48. Mayol X., Grana X., Baldi A., Sang A.N., Hu Q., Giordano A. Cloning of a new members of the retinoblastoma gene family (pRb2) which binds to the E1A transforming domain. Oncogene. 8:1993;2561-2566.
49. Claudio P.P., Howard C.M., Baldi A., De Luca A., Fu Y., Condorelli G., et al. pRb2/p130 has growth suppressive properties similar to yet distinctive from those of the retinoblastoma family members pRb and p107. Cancer Res. 54:1994;5556-5560.
50. Baldi A., De Luca A., Claudio P.P., Giordano G.G., Tommasino M., Paggi M.G., Giordano A. The Rb2/p130 gene product is a nuclear protein whose phosporylation is cell cycle regulated. J. Cell Biochem. 59:1995;402-408.
51. Susini T., Baldi F., Howard C.M., Baldi A., Taddei G., Massi D., et al. Expression of the retinoblastoma-related gene Rb2/p130 correlates with clinical outcome in endometrial cancer. J. Clin. Oncol. 16:1998;1085-1093.
52. Susini T., Massi D., Paglierani M., Masciullo V., Scambia G., Giordano A., et al. Expression of the retinoblastoma-related gene Rb2/p130 is downregulated in atypical endometrial hyperplasia and adenocarcinoma. Hum. Pathol. 32:2001;360-367.
53. Milde-Langosch K., Goemann C., Methner C., Rieck G., Bamberger A.-M., Loning T. Expression of Rb2/p130 in breast and endometrial cancer: correlations with hormone receptor status. Br. J. Cancer. 85:2001;546-551.
54. Kamb A., Gruis N.A., Waever-Feldhaus J., Liu Q., Harshman K., Tavtigian S.V., et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 264:1994;436-440.
55. Nobori T., Miura K., Wu D.J., Lois A., Takabayashi K., Carson D.A. Delections of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature. 368:1994;753-756.
56. Cairns P., Polascik T.J., Eby Y., Tokino K., Califano J., Merlo A., et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nature Genet. 11:1995;210-212.
57. Herman J.G., Merlo A., Mao L., Lapidus R.G., Issa J.-P.J., Davidson N.E., et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 55:1995;4525-4530.
58. Gonzales-Zulueta M., Bender C.M., Yang A.S., Nguyen T., Beart R.W., van Tornout J.M., Jones P.A. Methylation of the 5′ CpG island of the p16/ CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res. 55:1995;4531-4535.
59. Hatta Y., Hirama T., Takeuchi S., Lee E., Pham E., Miller C.W., et al. Alterations of the p16 (MTS1) gene in testicular, ovarian, and endometrial malignancies. J. Urol. 154:1995;1954-1957.
60. INK4B alterations in primary gynecologic malignancy. Gynecol. Oncol. 65:1997;319-324.
61. Koul A., Willen R., Bendahl P.-O., Nilbert M., Borg A. Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis. Cancer. 94:2002;2369-2379.
62. INK4A alterations are accompanied by aberrant protein immunostaining in endometrial carcinomas. J. Cancer Res. Clin. Oncol. 129:2003;589-596.
63. Peiffer S.L., Bartsch D., Whelan A.J., Mutch D.G., Herzog T.J., Goodfellow P.J. Low frequency of CDKN2 mutation in endometrial carcinomas. Mol. Carcinog. 13:1995;210-212.
64. Nakashima R., Fujita M., Enomoto T., Haba T., Yoshino K., Wada H., et al. Alteration of p16 and p15 genes in human uterine tumours. Br. J. Cancer. 80:1999;458-467.
65. Salvesen H.B., Das S., Akslen L.A. Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis. Clin. Cancer Res. 6:2000;153-159.
66. INK4A in primary gynecologic malignancy. Cancer Lett. 136:1999;231-235.
67. Tsuda H., Yamamoto K., Inoue T., Uchiyama I., Umesaki N. The role of p16-cyclinD/CDK-pRb pathway in the tumorigenesis of endometrioid-type endometrial carcinoma. Br. J. Cancer. 82:2000;675-682.
68. Esteller M., Corn P.G., Baylin S.B., Herman J.G. A gene hypermethylation profile of human cancer. Cancer Res. 61:2001;3225-3229.
69. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA. 93:1996;9821-9826.
70. McCluggage W.G., Jenkins D. p16 Immunoreactivity may assist in the distinction between endometrial and endocervical adenocarcinoma. Int. J. Gynecol. Pathol. 22:2003;231-235.
71. Kim J.W., Lee Y.S., Kim B.K., Park D.C., Lee J.M., Kim I.K., Namkoong S.E. Cell cycle arrest in endometrial carcinoma cells exposed to gonadotropin-releasing hormone analog. Gynecol. Oncol. 73:1999;368-371.
72. Sherr C.J. Mammalian G1 cyclins. Cell. 73:1993;1059-1065.
73. Lucas J., Pagano M., Staskova Z., Dreatta G., Bartek J. Cyclin D1 oscillates and is essential for cell cycle progression in human tumor cell lines. Oncogene. 9:1994;707-718.
74. Wang T.C., Cardiff R.D., Zukerberg L., Lees E., Arnold E., Schmidt V. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature. 369:1994;669-671.
75. Gillett C., Fantl V., Smith R., Fisher C., Bartek J., Dickson C., et al. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res. 54:1994;1812-1817.
76. Bartkova J., Lucas J., Muller H., Strauss M., Gusterson B., Bartek J. Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer. Cancer Res. 55:1995;949-956.
77. Nichols G.E., Williams M.E., Gaffey M.J., Stoler M.H. Cyclin D1 gene expression in human cervical neoplasia. Mod. Pathol. 9:1996;418-425.
78. Worsley S.D., Ponder B.A.J., Davis R.R. Overexpression of cyclin D1 in epithelial ovarian tumors. Gynecol. Oncol. 64:1997;189-195.
79. Michalides R., Hageman P., van Tinteren H., Houben L., Weintjens E., Klompmaker R., Peterse J. A clinicopathologic study on overexpression of cyclin D1 and p53 in a series of 248 patients with operable breast cancer. Br. J. Cancer. 73:1996;728-734.
80. Proctor A.J., Combs L.M., Cairn J.P., Knowles M.A. Amplification at chromosome 11q13 in transitional cell tumors of the bladder. Oncogene. 6:1991;789-795.
81. Nikaido T., Li S.F., Shiozawa T., Fujii S. Coabnormal expression of cyclin D1 and p53 protein in human uterine endometrial carcinomas. Cancer. 78:1996;1248-1253.
82. Ito K., Sasano H., Yoshida Y., Sato S., Yajima A. Immunohistochemical study of cyclins D and E and cyclin dependent kinase (cdk) 2 and 4 in human endometrial carcinoma. Anticancer Res. 18:1998;1661-1664.
83. Narita F., Sato A., Hamana S., Deguchi M., Otani T., Maruo T. Simultaneous immunohistochemical localization of β-catenin and cyclin D1 in differentiated but not in undifferentiated human endometrial carcinoma. Eur. J. Gynaecol. Oncol. 24:2003;129-134.
84. Quddus M.R., Latkovich P., Castellani W.J., Sung C.J., Steinhoff M.M., Briggs R.C., Miranda R.N. Expression of cyclin D1 in normal, metaplastic, hyperplastic endometrium and endometrioid carcinoma suggests a role in endometrial carcinogenesis. Arch. Pathol. Lab. Med. 126:2002;459-463.
85. Soslow R.A., Shen P.U., Chung M.H., Isacson C., Baergen R.N. Cyclin D1 expression in high-grade endometrial carcinomas-association with histologic subtype. Int. J. Gynecol. Pathol. 19:2000;329-334.
86. Smid-Koopman E., Blok L.J., Chadha-Ajwani S., Helmerhorst T.J.M., Brinkmann A.O., Huikeshoven F.J. Gene expression profiles of human endometrial cancer samples using a cDNA-expression array technique: assessment of an analysis method. Br. J. Cancer. 83:2000;246-251.
87. Schmitz M.J., Hendricks D.T., Farley J., Taylor R.R., Geradts J., Rose G.S., Birrer M.J. p27 and cyclin D1 abnormalities in uterine papillary serous carcinoma. Gynecol. Oncol. 77:2000;439-445.
88. Adams P.D. Regulation of the retinoblastoma tumor suppresor protein by cyclin/cdks. Biochem. Biophys. Acta. 1471:2001;M123-M133.
89. INK4 in human endometrioid-type endometrial carcinoma. Cancer. 80:1997;2250-2256.
90. Hashiguchi Y., Tsuda H., Yamamoto K., Inoue T., Ishiko O., Ogita S. Combined analysis of p53 and RB pathways in epithelial ovarian cancer. Hum. Pathol. 32:2001;988-996.
91. Milde-Langosch K., Hagen M., Bamberger A.-M., Loning T. Expression and prognostic value of the cell-cycle regulatory proteins, Rb, p16MTS1, p21WAF1, p27KIP1, cyclin E, and cyclin D2 in ovarian cancer. Int. J. Gynecol. Pathol. 22:2003;168-174.
92. Skomedal H., Kristensen G.B., Lie A.K., Holm R. Aberrant expression of the cell cycle associated proteins TP53, MDM2, p21, p27, cdk4, cyclin D1, RB, and EGFR in cervical carcinomas. Gynecol. Oncol. 73:1999;223-228.
93. INK4a/Rb/cyclin-D1 pathway in vulvar carcinoma, vulvar intraepithelial neoplasia, and lichen sclerosus. Hum. Pathol. 33:2002;1120-1125.
94. Bokhman J.V. Two pathogenetic types of endometrial carcinoma. Gynecol. Oncol. 15:1983;10-17.
95. Deligdisch L., Holinka C.F. Endometrial carcinoma: two diseases? Cancer Detect. Prev. 10:1987;237-246.
96. Caduff R.F., Svoboda-Neumann S.M., Johnston C.M., Bartos R.E., Frank T.S. Molecular analysis in endometrial cancer. Verh. Dtsch. Ges. Path. 81:1997;219-227.
97. Sherman M.E. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod. Pathol. 13:2000;295-308.
98. Matias-Guiu X., Catasus L., Bussaglia E., Lagarda H., Garcia A., Pons C., et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum. Pathol. 32:2001;569-577.
99. Lax S.F. Dualistic model of molecular pathogenesis in endometrial carcinoma. Zentralbl. Gynecol. 124:2002;10-16.
100. Semczuk A., Berbec H., Kostuch M., Cybulski M., Wojcierowski J., Baranowski W. K-ras gene point mutations in human endometrial carcinomas: correlation with clinicopathological features and patients' outcome. J. Cancer Res. Clin. Oncol. 124:1998;695-700.
101. Tashiro H., Isacson C., Levine R., Kurman R.J., Cho K.R., Hendrick L. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am. J. Pathol. 150:1997;177-185.
102. Sherman M.E., Bur M.E., Kurman R.J. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum. Pathol. 26:1995;1268-1274.
103. Risinger J.I., Maxwell G.L., Berchuck A., Barrett J.C. Promoter hypermethylation as an epigenetic component in type I and type II endometrial cancers. Ann. N. Y. Acad. Sci. 983:2003;208-212.
104. Barbieri F., Cagnoli M., Ragni N., Pedulla F., Foglia G., Alama A. Expression of cyclin D1 correlates with malignancy in human ovarian tumours. Br. J. Cancer. 75:1997;1263-1268.
105. Dong Y., Walsh M.D., McGuckin M.A., Cummings M.C., Gabrielli B.G., Wright G.R., et al. Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer. Int. J. Cancer. 74:1997;407-415.
106. Kusume T., Tsuda H., Kawabata M., Inoue T., Umesaki N., Suzuki T., Yamamoto K. The p16-cyclinD1/CDK4-pRb pathway and clinical outcome in epithelial ovarian cancer. Clin. Cancer Res. 5:1999;4152-4157.